BYSI Stock Forecast: BeyondSpring, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.31
−28.42% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 11 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$18.1M
Ticker Nerd rank
11/ 100
Median analyst target
—
Analysts covering
—
Revenue$0.0
Operating income−$1.7M
Net income−$5.7M
Free cash flow−$3.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−48.0%
1M
−40.2%
YTD
−80.8%
1Y
−82.0%
From 52W high
−86.7%
From 52W low
0.0%
$0.31
$2.35
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores BeyondSpring, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
11/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
47
Volatility
39
Momentum
32
Accruals
29
Value
23
Revisions
20
Quality
11
Growth
10

Issuance (47): The share count has been shrinking and the company is not leaning on new borrowing.

Growth (10): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

BYSI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BYSI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$0.50$1.00$1.50$2.00$2.50Jan 26Apr 26Jul 26Oct 26BYSI

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
2 May 2023BairdMaintainsOutperform$4.00 → $1.25
2 Dec 2021B of A SecuritiesDowngradeUnderperform—
2 Dec 2021JefferiesDowngradeHold—
1 Dec 2021HC Wainwright & Co.DowngradeNeutral—
20 Sept 2021HC Wainwright & Co.MaintainsBuy—
9 Sept 2021BairdInitiatesOutperform—
4 Aug 2021HC Wainwright & Co.UpgradeBuy—
5 Apr 2021HC Wainwright & Co.DowngradeNeutral—
11 Jan 2021B of A SecuritiesInitiatesBuy—
29 Dec 2020Evercore ISI GroupInitiatesOutperform—
15 June 2020HC Wainwright & Co.MaintainsBuy—
30 Mar 2020HC Wainwright & Co.MaintainsBuy—
7 Feb 2020JefferiesInitiatesBuy—
10 Jan 2020NomuraInitiatesBuy—
10 Jan 2020Nomura InstinetInitiatesBuy—
3 Dec 2019William BlairInitiatesOutperform—
22 June 2018Maxim GroupMaintainsBuy—
4 Apr 2017Rodman & RenshawInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

BYSI appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

BYSI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, BeyondSpring, Inc. returned −82.0% against +6.9% for the S&P 500, dividends included.

BYSI vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120140Jan 26Apr 26Jul 26Oct 26BYSIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BYSI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−22.4%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • BeyondSpring, Inc. has a market value of $18.1M and an enterprise value of $17.6M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$23.1M.

  • Free cash flow in the twelve months to 30 June 2026: −$16.7M.

  • Shares outstanding: 41.1M.

  • BeyondSpring, Inc. employs 44 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

BYSI and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BYSIBeyondSpring, Inc.$18.1M11
ACTUActuate Therapeutics, Inc.$13.6M39
NCELNewCelX Ltd.$13.6M4
PLURPluri, Inc.$13.5M17
ESLAEstrella Immunopharma, Inc.$13.5M26
ABOSAcumen Pharmaceuticals, Inc.$13.5M42
CTXRCitius Pharmaceuticals, Inc.$14.0M34

Take a look at BYSI’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own BeyondSpring, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about BYSI

How does Ticker Nerd's model rank BYSI?

As at 21 Nov 2026, BeyondSpring, Inc. ranks 11 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Issuance (47 of 100).

What is the BYSI stock forecast for 2030?

No analyst covering BeyondSpring, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BYSI are extrapolating price history, which says nothing about the business.

How has BYSI stock performed over the past year?

BeyondSpring, Inc. returned -82.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does BeyondSpring, Inc. do?

BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing oncology therapies, with an emphasis on immuno-oncology and cancer-supportive care. The company’s core programs center on Plinabulin, a lead candidate being studied for use in non-small cell lung cancer and in the prevention of chemotherapy-induced neutropenia, a condition that can complicate cancer treatment.

Company

About BeyondSpring, Inc.

BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing oncology therapies, with an emphasis on immuno-oncology and cancer-supportive care. The company’s core programs center on Plinabulin, a lead candidate being studied for use in non-small cell lung cancer and in the prevention of chemotherapy-induced neutropenia, a condition that can complicate cancer treatment. BeyondSpring also operates a TPD platform that supports the discovery and development of therapeutic agents and new chemical entities. Its work is directed at addressing unmet needs in cancer care through targeted drug development and clinical research. Headquartered in Florham Park, New Jersey, BeyondSpring Inc. plays a specialized role in the biotechnology market as a research-driven company advancing late-stage and early-stage therapeutic candidates.

CEO Dr. Lan Huang Ph.D. · 44 employees · United States · https://beyondspringpharma.com